These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32502983)

  • 21. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
    Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
    Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erdheim-Chester disease.
    Campochiaro C; Tomelleri A; Cavalli G; Berti A; Dagna L
    Eur J Intern Med; 2015 May; 26(4):223-9. PubMed ID: 25865950
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.
    Cao XX; Sun J; Li J; Zhong DR; Niu N; Duan MH; Liang ZY; Zhou DB
    Ann Hematol; 2016 Apr; 95(5):745-50. PubMed ID: 26858028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia].
    Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
    Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report.
    Tamura S; Kawamoto K; Miyoshi H; Suzuki T; Katagiri T; Kasami T; Nemoto H; Miyakoshi S; Kobayashi H; Shibasaki Y; Masuko M; Takeuchi K; Ohshima K; Sone H; Takizawa J
    J Clin Exp Hematop; 2018 Dec; 58(4):161-165. PubMed ID: 30305475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Profound systemic alteration of the immune phenotype and an immunoglobulin switch in Erdheim-Chester disease in 78 patients from a single center.
    Aubart FC; Poupel L; Saint-Charles F; Charlotte F; Arsafi Y; Frisdal E; Roos-Weil D; Emile JF; Amoura Z; Guerin M; Lesnik P; Haroche J; Le Goff W
    Haematologica; 2022 Jun; 107(6):1347-1357. PubMed ID: 34647443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease.
    Saunders IM; Goodman AM; Kurzrock R
    Oncologist; 2020 Feb; 25(2):e386-e390. PubMed ID: 32043767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and Neuroimaging Manifestations of Erdheim-Chester Disease: A Review.
    Garg N; Lavi ES
    J Neuroimaging; 2021 Jan; 31(1):35-44. PubMed ID: 32920940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dabrafenib and steroids for the treatment of Erdheim-Chester disease with extensive CNS involvement: a case report.
    Yuen CA; Bao S; Aung MS; Shishodia R; Kong XT
    Per Med; 2024; 21(2):71-78. PubMed ID: 38275171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erdheim-Chester disease.
    Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
    Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis.
    Perić P; Antić B; Knezević-Usaj S; Radić-Tasić O; Radovinović-Tasić S; Vasić-Vilić J; Sekulović L; Tarabar O; Tukić L; Jovandić S; Magić Z
    Vojnosanit Pregl; 2016 Jan; 73(1):83-7. PubMed ID: 26964390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erdheim-Chester Disease: a Rare but Important Cause of Recurrent Pericarditis.
    Chahine J; Alzubi J; Alnajjar H; Ramchand J; Chetrit M; Klein AL
    Curr Cardiol Rep; 2020 Jun; 22(8):75. PubMed ID: 32607694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective.
    Kanakis M; Petrou P; Lourida G; Georgalas I
    Surv Ophthalmol; 2022; 67(2):388-410. PubMed ID: 34081930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Saving orphans: BRAF targeting of histiocytosis.
    Heaney ML
    Blood; 2013 Feb; 121(9):1487-8. PubMed ID: 23449613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CNS Erdheim-Chester Disease: A Challenge to Diagnose.
    Pan Z; Kleinschmidt-DeMasters BK
    J Neuropathol Exp Neurol; 2017 Dec; 76(12):986-996. PubMed ID: 29096034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erdheim-Chester disease and vemurafenib: a review of ophthalmic presentations and clinical outcomes.
    Park JK; Huang LC; Kossler AL
    Orbit; 2023 Jun; 42(3):233-244. PubMed ID: 35702885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erdheim-Chester disease associated with a novel, complex BRAF p.Thr599_Val600delinsArgGlu mutation.
    Bentel JM; Thomas MA; Rodgers JJ; Arooj M; Gray E; Allcock R; Fermoyle S; Mancera RL; Cannell P; Parry J
    BMJ Case Rep; 2017 Apr; 2017():. PubMed ID: 28455460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erdheim-Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances.
    Haroun F; Millado K; Tabbara I
    Anticancer Res; 2017 Jun; 37(6):2777-2783. PubMed ID: 28551613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Erdheim-Chester disease: a systematic review.
    Cives M; Simone V; Rizzo FM; Dicuonzo F; Cristallo Lacalamita M; Ingravallo G; Silvestris F; Dammacco F
    Crit Rev Oncol Hematol; 2015 Jul; 95(1):1-11. PubMed ID: 25744785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the BRAF pathway in haematological diseases.
    Rees MJ; Dickinson M; Paterson J; Ng TF; Grigg A; Moore J; Blombery P; Seymour JF
    Intern Med J; 2023 May; 53(5):845-849. PubMed ID: 37222093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.